Halo Labs Unveils Aura+ Subscription Program for Convenient and Affordable Particle Analysis See more here
Read More
Halo Labs Completes $6M Series C Growth Financing See more here
Read More
Halo Labs Launches New Instruments for Protein, Cell, and Gene Therapy Developers Aura PTx analyzes degraded excipients in protein therapeutics, and Aura+ is an all-in-one drug product quality tool for mAb, cell, and gene therapy See more here
Read More
Halo Labs Launches the Aura GT™ for Gene Therapy Product Quality Aura GT is the first system specifically designed to quantify capsid aggregates and identify the mechanism of aggregation See more here
Read More
Halo Labs Launches the Aura CL™ for Cell Therapy Product Quality Aura CL is the first system specifically designed to quantify cell aggregates and ID cell vs non-cell contaminants See more here
Read More
Halo Labs Announces New Products and Leadership Changes Dr. Joseph Keegan, Executive Chairman, to Assume Interim Leadership See more here
Read More
Halo Labs Launches Aura for Particle and Aggregate ID in Biotherapeutic Development Aura revolutionizes biologic stability analysis, enabling simple protein and non-protein aggregate identification in formulation development and analytical testing See more here
Read More
Halo Labs Raises $12M in Series B1 Financing Round and Enters into the FDA Market See more here
Read More
Philadelphia scientific instruments developer raises $5.6M See more here
Read More